Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Jefferam1on Jul 24, 2018 4:36pm
158 Views
Post# 28361337

RE:News impending, horrible idea to dump shares right now

RE:News impending, horrible idea to dump shares right nowBy news I'm assuming you mean the start date for the next trial which is expected to start some tiem in August?
Also do they have a partnership for this trial? I assume the TopStone deal was only for the one trial and they will need to secure another partner for this one (which could end up being Topstone) but I dont' believe it's known yet?
I tried asking Christina about this and she never responded which is odd as she is normally pretty good at getting back to me.

The only other news I could see that would help is if they secured another small regional partnership, but I don't have any high hopes on this happening any time soon. Would just be a pleasant surprsie. 

As I've previously said, the big block buster news of a partnership that makes us the money, I don't expect to hear until sometime first 1/2 next year. After we get the data back from this final Phase 2B trial.

That will set us up for  two Phase 3 trials in 2019 and 2020 plus all the work required prior to going to Market. By 2021 we should see our first sale of ATB-346.
2022 we should have a year of sales and wow will that be amazing. 
Not sure if any of you intended to have shares left by then, but I know will still have a healthy amount, that is unless we had a complete take out in 2019.

Either way, will be a good future. Patience(or accumulation) is key right now.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities